Moving from Preclinical to Clinical Studies
|
|
- Jeremy Johns
- 6 years ago
- Views:
Transcription
1 Global Product Patient Safety Biomarkers for DILI: Moving from Preclinical to Clinical Studies Arie Regev, M.D. Global Patient Safety Eli Lilly and Company Indianapolis, IN
2 New IDILI Biomarkers in the Clinic: State of the Art Number of new IDILI biomarkers in clinical practice in the last 40 years: Number of new IDILI biomarkers currently in clinical development: Number of drugs for which IDILI mechanism is completely understood: Number of widely accepted animal models for IDILI: Number of clinicians and basic-research scientists who agree with each other on IDILI biomarkers: Too Low
3 Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
4 Blind Men and an Elephant
5 Blind Men and an Elephant It s an elephant It s an elephant It s an elephant It s an elephant
6 DILI- Not a Single Entity Dose Dependent DILI Idiosyncratic DILI Isoniazid Amoxicillin-Clavulanate Methotrexate Main biomarker- ALT Main biomarker- AlkP Main biomarker-?
7 ALT in Methotrexate induced Liver Injury No significant differences in ALT or AST between patients that developed severe liver fibrosis and those that did not. Rosenberg, J Hepatol 2007;46:111-8 Berends, Aliment Pharmacol Ther 2006;24:
8 DILI- Not a Single Entity (Cont ) Amoxicillin-Clavulanate induced Cholestatic injury Amoxicillin-Clavulanate induced Hepatocellular injury? Hepatocellular DILI due to drug X in patient A Hepatocellular DILI due to drug X in patient B?
9 Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
10 Potential Roles for Biomarkers in Hepatocellular DILI (I) 1. Detection of susceptibility to DILI (susceptibles vs tolerators/adaptors) during early drug development N/A Hy s Rule prior to exposure N/A during drug treatment N/A N/A 2. Identifying drugs capable of causing severe DILI
11 Potential Roles for Biomarkers in Hepatocellular DILI (II) 1. Detection of liver injury at an early injury stage in a mild injury 2. Differentiation of liver injury from injuries of other organs (e.g. muscle) ALT ALT 3. Differentiation of significant liver injury from transient ALT changes (susceptibles vs. tolerators/adaptors) 4. Prediction of severe outcome (live failure) Hepatocellular DILI!! ALT/AST, N/A CPK Liver-specific mrna 1,2 N/A 5. Differentiate DILI from other causes of liver injury N/A N/A 1. Miyamoto et al. Toxicological Sciences 2008;106: Wetmore et al. Hepatology. 2010;51:
12 Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
13 Multinational pharmaceutical company survey 12 pharmaceutical companies, 150 compounds Examined the percentage of human drug toxicities that had previously occurred in animal studies
14 Animal Concordance by Human Toxicity Category. Olson et al. Regulatory Toxicology and Pharmacology 2000; 32: 56 67
15 Company Confidential Copyright 2007 Eli Lilly and Company
16 Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
17 Is ALT a Gold Standard? ALT
18 Is ALT a Gold Standard?
19 Vector Analysis to Detect Hepatotoxicity Signals The ALT Worship Trost, Freston. Drug Information Journal 2008;42:27-34
20 ALT Levels in Patients with Idiosyncratic DILI (2)
21 ALT Levels in Patients with Idiosyncratic DILI (2) Mindikoglu, Magder, Regev. Liver Transplantation 2009; 15:
22 Kechagias et al. Gut 2008
23 Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
24 Summary: Conditions for Success of Future Translational Work on DILI Biomarkers 1. Understand the types of DILI in humans and their diverse clinical presentation 2. Focus on the questions that IDILI biomarkers need to address in the clinic 3. Know the limitations of animal studies and in-vitro models in the study of IDILI 4. Know the clinical strengths and shortcomings of existing DILI biomarkers (e.g. ALT, AST, AlkP, TBIL, GGT, etc.) 5. Continue communication between preclinical scientists and clinicians throughout the biomarker development process
25 Global Product Patient Safety Thank you
HBV Forum 2 April 18 th 2017 Hilton Amsterdam.
HBV Forum 2 April 18 th 2017 Hilton Amsterdam www.forumresearch.org Detection, Assessment and Management of DILI During Drug Development for HBV: The IQ DILI Initiative. Arie Regev, MD Global Patient Safety
More informationLeonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation
Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network Click to view Biosketch and Presentation Abstract or page down to review presentation ALT as a Biomarker for Drug-Induced Liver Injury Leonard
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More informationDILI: Clinical Pharmacology Considerations for Risk Assessment
DILI: Clinical Pharmacology Considerations for Risk Assessment Raj Madabushi, PhD Office of Clinical Pharmacology Drug-Induced Liver Injury (DILI) Conference XVII June 06, 2017 Disclaimer: The views expressed
More informationHepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA
Hepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA Disclaimer The findings and conclusions in this presentation have not been formally disseminated by the Food and Drug
More informationDrug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School
Drug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School Disclosures None pertaining to current talk Research grants from Gilead,
More informationDrug Induced Liver Injury: A Clinical Perspective. Robert J. Fontana, MD
Drug Induced Liver Injury: A Clinical Perspective Robert J. Fontana, MD Drug induced liver injury (DILI) is an uncommon cause of acute and chronic liver injury of increasing importance to patients, clinicians,
More informationSerum microrna biomarkers for human DILI
CLEARANCE DRUG bioactivation covalent binding Detoxication GLUCURONIDE SULPHATE DRUG + METABOLITE chemical stress mitochondrial dysfunction apoptosis necrosis hepatocyte hypertrophy hepatocyte hyperplasia
More informationContextual graphics. Making narratives smarter. Michael Merz, MD Spotfire User Group Meeting, Basel Nov 3, 2016
Novartis Institutes for BioMedical Research Contextual graphics Making narratives smarter Michael Merz, MD Spotfire User Group Meeting, Basel Nov 3, 2016 Outline Drug-induced liver injury (DILI) as an
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationx B versus x ULN for Assessing Drug Effects
x B versus x ULN for Assessing Drug Effects Leonard B. Seeff, M.D. The Hill Group and the U.S. Food and Drug Administration Detecting and Evaluating Drug-Induced Liver Injury and Dysfunction University
More informationThe Future Outlook to DILI Research From The Perspective of China
The Future Outlook to DILI Research From The Perspective of China Yimin Mao Renji Hospital,Shanghai Jiaotong University School of Medicine DILI in General Population Less than 20/100,000 The incidence
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationThe liver in poisoning: what can we learn from animal models?
The liver in poisoning: what can we learn from animal models? Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital 4031 Basel/Switzerland Kraehenbuehl@uhbs.ch Outcome and causes of
More informationIs there a common mechanism of DILI, do we need to know?
Is there a common mechanism of DILI, do we need to know? Neil Kaplowitz, MD USC Research Center for Liver Disease Los Angeles, California IS THERE A COMMON MECHANISM OF DILI? ANSWER YES & NO Mechanisms
More informationDrug- induced Liver Injury. Guruprasad P. Aithal
Drug- induced Liver Injury Guruprasad P. Aithal Characterising DILI Deriving case defini=ons Phenotypes and outcomes Manifesta=ons PaBerns Liver histology Cholestasis Terminology Drug- induced Liver disease:
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationPositive Rechallenge: What Clinical Trial Data Tell Us Julie Papay, Pharm.D. UCB BioSciences Global Patient Safety
Positive Rechallenge: What Clinical Trial Data Tell Us Julie Papay, Pharm.D. UCB BioSciences Global Patient Safety Drug-Induced Liver Injury (DILI) Conference XVI Wednesday 23 March 2016 The comments provided
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationWoman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP
Woman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP IN THIS ARTICLE Results of case patient s initial laboratory work-up, page 39 Top 10 prescription medications associated with idiosyncratic
More information19 March 2014 DILI Conferences 1
John R. Senior, M.D. Associate Director for Science Office of Pharmacovigilance and Epidemiology Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
More informationAppropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach
Appropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach Veterinary Pathology 49(2) 357-361 ª The Author(s) 2012 Reprints and permission: sagepub.com/journalspermissions.nav
More informationClick to view Biosketch and Presentation Abstract or page down to review presentation
Alexander Gerbes, MD Professor of Internal Medicine, Medizinische Klinik und Poliklinik II Klinikum der Universität München, FRG Andreas Benesic, MD Physician, Researcher Medizinische Klinik und Poliklinik
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationPrediction of Drug Induced Liver Disease, Pre and Post Marketing
Prediction of Drug Induced Liver Disease, Pre and Post Marketing Sovani Vishwas ABSTRACT Drug induced liver disease is one of the most important causes of drug withdrawals post marketing. The liver is
More informationRecent Status of Drug-induced Liver Injury and Its Problems in Japan
Research and Reviews Recent Status of Drug-induced Liver Injury and Its Problems in Japan JMAJ 53(4): 243 247, 2010 Hajime TAKIKAWA* 1 Abstract Adverse drug reactions are becoming a social issue in recent
More informationThe Burden of Drug Induced Liver Injury
The Burden of Drug Induced Liver Injury Victor J. Navarro, MD Chairman, Division of Hepatology Einstein Healthcare Network Professor of Medicine Jefferson Medical College Philadelphia, PA, USA Victor J.
More informationDo Histological Features Inform DILI mechanisms?
Do Histological Features Inform DILI mechanisms? Drug-Induced Liver Injury (DILI) Conference XVII June, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Disclosures No financial or other conflicts
More informationHerbal Supplements and the Liver. Lauren Myers PA-C, MMsc
Herbal Supplements and the Liver Lauren Myers PA-C, MMsc The Planner Lauren Myers, MMSc, PA-C - have no relevant financial relationships to disclose. Herbal Dietary Supplements in the US 42% of Americans
More informationDrug Induced Liver Injury. Case. Case 8/8/2016. Donald Gardenier, DNP, FNP BC, FAAN, FAANP Desert Oasis Health Care Palm Springs, CA
Drug Induced Liver Injury Donald Gardenier, DNP, FNP BC, FAAN, FAANP Desert Oasis Health Care Palm Springs, CA Case 28 year old white male PMHx Grave s disease; Rx levothyroxine 175 mcg No recent travel
More informationTranslatability of cytokine data: from animals to humans. Marie-Soleil Piche, PhD Associate Scientific Director of Immunology Charles River, Montreal
Translatability of cytokine data: from animals to humans Marie-Soleil Piche, PhD Associate Scientific Director of Immunology Charles River, Montreal Presentation outline Overview of cytokines Factors related
More informationShould There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD
Should There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD Drug-Induced Liver Injury: Are We Ready to Look? March 23-24,2011 AASLD, FDA/CDER, PhRMA A Common Statement
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More information1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?
Drug Induced Liver Injury Cases Case #1 A.S., a16 year-old female, was found by her pediatrician to be slightly jaundiced during a routine school physical. She denied any history of liver disease, abdominal
More informationPreclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer
Preclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer Scott Laurie MD, FRCPC The Ottawa Hospital Cancer Centre Associate Professor, University of Ottawa Disclosures I have no
More informationImpacts of simultaneous administration of omega-3 fatty acids with amoxicillin/clavulanic acid on albino rats' liver and bile
Research Article Impacts of simultaneous administration of omega-3 fatty acids with amoxicillin/clavulanic acid on albino rats' liver and bile Alaa K. J. Al-Rikabi *1, Nada N Alshawi 2 1 Poisoning consultation
More informationDebate Drug Induced Liver Disease In The East - Current Status
Debate Drug Induced Liver Disease In The East - Current Status Deepak Amarapurkar Consultant Gastroenterologist and Hepatologist Bombay Hospital & medical Research Centre, & Breach Candy Hospital Mumbai
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationLa Steatosi epatica nel paziente con infezione da HIV
La Steatosi epatica nel paziente con infezione da HIV Dott. Nicola Squillace Clinica delle Malattie infettive ASST-Monza, Ospedale San Gerardo-Università di Milano-Bicocca Introduction/Background Definition
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationThe predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning
The predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning Khalid Al-Hourani, Rachel Mansi, Janice Pettie, Margaret Dow, Nick Bateman
More informationAn oncology reviewer s perspective on hepatotoxicity
An oncology reviewer s perspective on hepatotoxicity Gideon Blumenthal, MD March 21 2013 FDA/Critical Path DILI conference Disclaimer: Views expressed herein are my own and may not necessarily reflect
More informationBRIDGE THE GAP A Human Pathways Approach to Disease Research
BRIDGE THE GAP A Human Pathways Approach to Disease Research BIOMED 21 Brussels December 8 th, 2015 Brigitte Landesmann Systems Toxicology Unit and EURL ECVAM Institute for Health and Consumer Protection
More informationYes, the proposed stopping rules are too conservative. John R. Senior, M.D. 25 March 2010 Rethink Stopping Rules 1
Yes, the proposed stopping rules are too conservative John R. Senior, M.D. 25 March 2010 Rethink Stopping Rules 1 Guidelines for study stop rules: ALT/AST > 8X ULN ALT/AST remains > 5X ULN over 2 wks ALT/AST
More informationForward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
More informationThe use of methotrexate in rheumatological conditions A review of the evidence. Maureen Cox January 2009
The use of methotrexate in rheumatological conditions A review of the evidence Maureen Cox January 2009 Visser et al Multinational evidence based recommendations for the use of methotrexate in rheumatic
More informationCan Study Protocols Protect Patients with Liver Diseases from Serious DILI?
Can Study Protocols Protect Patients with Liver Diseases from Serious DILI? Serious DILI John M Vierling, MD, FACP, FAASLD Professor of Medicine and Surgery Chief of Hepatology Director of Baylor Liver
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationSponsor. Generic Drug Name. Trial Indication(s) Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Novartis.
Sponsor Novartis Generic Drug Name Lumiracoxib Trial Indication(s) Not applicable Protocol Number CCOX189A2483 Protocol Title A retrospective pharmacogenetics analysis of patients with elevated liver enzymes
More informationmirnas as Biomarkers for Drug-Induced Liver Injury and as Predictors in Clinical Trials
mirnas as Biomarkers for Drug-Induced Liver Injury and as Predictors in Clinical Trials Herbert L. Bonkovsky, M.D. Professor of Medicine Wake Forest University School of Medicine Chief of Hepatology, NC
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationEvaluation of prognostic markers in severe drug-induced liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2007 January 28; 13(4): 628-632 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 The WJG Press. All rights reserved. RAPID COMMUNICATION
More informationA Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital
J Korean Med. 2016;37(2):119-124 pissn 1010-0695 eissn 2288-3339 Case Report A Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital Chang-Gue Son Liver and Immunology Research
More informationALS ACT (Accelerated Therapeutics)
ALS ACT (Accelerated Therapeutics) Request for Proposals: Phase II Clinical development of novel, high-potential treatments for people with ALS Release Date 23 October 2015 Letter of intent due: November
More informationResearch in Hepatology What is hot and what is not!
Research in Hepatology What is hot and what is not! Anna SF Lok, MD University of Michigan Ann Arbor, MI, USA Please consider the environment before printing this PowerPoint Outline How to define hot?
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationInhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury
Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Kenneth R. Brouwer, Ph.D., RPh Chief Scientific Officer DDI Meeting June 2017 Seattle, Washington
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationDR SAMEER GULATI MD, FIACM, FIMSA
DR SAMEER GULATI MD, FIACM, FIMSA ASSISTANT PROFESSOR DEPT OF MEDICINE VMMC & SAFDARJUNG HOSPITAL, DELHI EULAR CERTIFICATION COURSE IN RHEUMATIC DISEASES EULAR CERTIFICATION COURSE IN MUSCULOSKELETAL ULTRASOUND
More informationVIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms
Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Definitions AST and ALT Markers of hepatocellular injury Ryan M. Ford, MD Assistant Professor of Medicine Director of Viral Hepatitis
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationDILI (Hepatotoxicidad)
DILI (Hepatotoxicidad) Raúl J Andrade Gastroenterology Service, University Hospital, Department of Medicine, University of Málaga, IBIMA and CIBERehd October 31, 2015 Drug-induced liver injury Relatively
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More information'The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury'.
'The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury'. Jaishvi Eapen, New York University Rotimi Ayoola, New York University Ram
More informationIntrinsic vs. Idiosyncratic DILI
Idiosyncratic Drug Induced Liver Injury Naga Chalasani, MD, FACG Professor & Director Division of GI and Hepatology Indiana University School of Medicine Clarian/IU Digestive Diseases Center ACG PG Course
More informationTherapies for DILI: NAC, Steroids or NRF-2 activators?
Therapies for DILI: NAC, Steroids or NRF-2 activators? William M. Lee, MD Professor of Internal Medicine Meredith Mosle Chair in Liver Diseases UT Southwestern Medical Center at Dallas Drug-Induced Liver
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationCase Report Diphenhydramine as a Cause of Drug-Induced Liver Injury
Hindawi Case Reports in Hepatology Volume 217, Article ID 3864236, 4 pages https://doi.org/1.1155/217/3864236 Case Report Diphenhydramine as a Cause of Drug-Induced Liver Injury Yunseok Namn, 1 Yecheskel
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationPaul B. Watkins 1 James H. Lewis. Jaime D. Blais 5 Dan M. Smotzer. Vicente E. Torres 6 Frank S. Czerwiec
Drug Saf (2015) 38:1103 1113 DOI 10.1007/s40264-015-0327-3 ORIGINAL RESEARCH ARTICLE Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease:
More informationA comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications
/, Vol.6, No. 19 A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications Zuquan Weng 1,*, Kejian Wang 1,*, Haibo
More informationCase Report Propylthiouracil-Induced Acute Liver Failure: Role of Liver Transplantation
International Endocrinology Volume 2010, Article ID 910636, 5 pages doi:10.1155/2010/910636 Case Report Propylthiouracil-Induced Acute Liver Failure: Role of Liver Transplantation Andres F. Carrion, 1
More informationIMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
More informationBackground. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
More informationTopic review - A patient with impaired liver function. Dr. Karen Hin Kwan Luk 18/1/2018
Topic review - A patient with impaired liver function Dr. Karen Hin Kwan Luk 18/1/2018 Case M/69 PMH: 1. Diabetes 2. Hypertension 3. Hyperlipidaemia 4. Paroxysmal supraventricular tachycardia 5. Cerebral
More informationClinical Policy Title: Liver elastography
Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August
More informationRecent Research Advances in Drug Induced Liver Injury
Recent Research Advances in Drug Induced Liver Injury Timothy M. Wright, MD Global Head of Translational Sciences Novartis Institutes of Biomedical Research, Cambridge, MA University of Michigan, Ann Arbor,
More informationSupplementary Online Content
Supplementary Online Content Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationAdversity in Toxicology Studies Setting the NOAEL
Adversity in Toxicology Studies Setting the NOAEL Regulatory Affairs & Drug Development : Current Thinking and Challenges April, 2017 Peter C. Mann, DVM, Dipl. ACVP, FIATP pmann@epl-inc.com Definitions
More informationMethodology to Assess Clinical Liver Safety Data
Drug Saf (2014) 37 (Suppl 1):S33 S45 DOI 10.1007/s40264-014-0184-5 REVIEW ARTICLE Methodology to Assess Clinical Liver Safety Data Michael Merz Kwan R. Lee Gerd A. Kullak-Ublick Andreas Brueckner Paul
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More information12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 28 September 2016
A Randomized, Single-Blind, Placebo-Controlled, Phase /2 Study of ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha- Antitrypsin Deficiency Associated Liver Disease: Interim Study
More informationAgents that inhibit the BSEP and mitochondrial function what do we know? Prepared by Michael D. Aleo, Ph.D. Groton, Investigative Toxicology
Agents that inhibit the BSEP and mitochondrial function what do we know? Prepared by Michael D. Aleo, Ph.D. Groton, Investigative Toxicology Declarations Nonclinical studies All procedures performed on
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationInteractive Case Presentation #3: A Case of Acute-on-Chronic Liver Disease
Interactive Case Presentation #3: A Case of Acute-on-Chronic Liver Disease Moderator: Angie Coste, MSN, CRM, FNP-C Texas Liver Institute San Antonio, Texas Case: Jocelyn A 55 year old Hispanic female presents
More information